Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor Tissue, Blood Serum and Urine of Patients with Renal Cell Carcinoma

R. Iliev, M. Fedorko, T. Machackova, H. Mlcochova, M. Svoboda, D. Pacik, J. Dolezel, M. Stanik, O. Slaby,

. 2016 ; 36 (12) : 6419-6423.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013356

Grantová podpora
NV15-31071A MZ0 CEP - Centrální evidence projektů
NV15-34678A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Renal cell carcinoma (RCC) is the most common neoplasm of adult kidney accounting for about 3% of adult malignancies. P-Element induced wimpy testis (PIWI)-interacting RNAs (piRNAs) are a new class of naturally occurring, short non-coding RNAs involved in silencing of transposable elements and in sequence-specific chromatin modifications. There were preliminary data published indicating that piR-823 expression is deregulated in circulating tumor cells and tumor tissue in gastric and kidney cancer, respectively. PATIENTS AND METHODS: In our study, we analyzed piR-823 levels in 588 biological specimens: tumor tissue (N=153), adjacent renal parenchyma (N=121), blood serum (N=178) and urine (N=20) of patients undergoing nephrectomy for RCC; and in blood serum (N=101) and urine (N=15) of matched healthy controls. Expression levels of piR-823 were determined in all biological specimens by quantitative real-time polymerase chain reaction, compared in patients and controls, and correlated with clinicopathological features of RCC. RESULTS: We identified a significant down-regulation of piR-823 in tumor tissue [p<0.0001, area under the curve (AUC)=0.7945]. On the contrary in blood serum and urine, the expression of piR-823 was significantly higher in patients with RCC compared to healthy individuals (p=0.0005, AUC=0.6264 and p=0.0157, AUC=0.7433, respectively). We further observed higher levels of piR-823 in tumor tissue to be associated with shorter disease-free survival of patients (p=0.0186) and a trend for higher piR-823 levels in serum to be associated with advanced clinical stages of RCC (p=0.0691). There were no other significant associations of piR-823 levels in any type of biological specimen with clinicopathological features of RCC. CONCLUSION: piR-823 is down-regulated in tumor tissue, but positively correlated with worse outcome, indicating its complex role in RCC pathogenesis. In blood serum, piR-823 is up-regulated, but with unsatisfactory analytical performance. Preliminary data indicate the promising diagnostic utility of urinary piR-823 in patients with RCC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013356
003      
CZ-PrNML
005      
20201116155030.0
007      
ta
008      
170413s2016 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.11239 $2 doi
035    __
$a (PubMed)27919963
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Iliev, Robert $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
245    10
$a Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor Tissue, Blood Serum and Urine of Patients with Renal Cell Carcinoma / $c R. Iliev, M. Fedorko, T. Machackova, H. Mlcochova, M. Svoboda, D. Pacik, J. Dolezel, M. Stanik, O. Slaby,
520    9_
$a BACKGROUND: Renal cell carcinoma (RCC) is the most common neoplasm of adult kidney accounting for about 3% of adult malignancies. P-Element induced wimpy testis (PIWI)-interacting RNAs (piRNAs) are a new class of naturally occurring, short non-coding RNAs involved in silencing of transposable elements and in sequence-specific chromatin modifications. There were preliminary data published indicating that piR-823 expression is deregulated in circulating tumor cells and tumor tissue in gastric and kidney cancer, respectively. PATIENTS AND METHODS: In our study, we analyzed piR-823 levels in 588 biological specimens: tumor tissue (N=153), adjacent renal parenchyma (N=121), blood serum (N=178) and urine (N=20) of patients undergoing nephrectomy for RCC; and in blood serum (N=101) and urine (N=15) of matched healthy controls. Expression levels of piR-823 were determined in all biological specimens by quantitative real-time polymerase chain reaction, compared in patients and controls, and correlated with clinicopathological features of RCC. RESULTS: We identified a significant down-regulation of piR-823 in tumor tissue [p<0.0001, area under the curve (AUC)=0.7945]. On the contrary in blood serum and urine, the expression of piR-823 was significantly higher in patients with RCC compared to healthy individuals (p=0.0005, AUC=0.6264 and p=0.0157, AUC=0.7433, respectively). We further observed higher levels of piR-823 in tumor tissue to be associated with shorter disease-free survival of patients (p=0.0186) and a trend for higher piR-823 levels in serum to be associated with advanced clinical stages of RCC (p=0.0691). There were no other significant associations of piR-823 levels in any type of biological specimen with clinicopathological features of RCC. CONCLUSION: piR-823 is down-regulated in tumor tissue, but positively correlated with worse outcome, indicating its complex role in RCC pathogenesis. In blood serum, piR-823 is up-regulated, but with unsatisfactory analytical performance. Preliminary data indicate the promising diagnostic utility of urinary piR-823 in patients with RCC.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a nádorové biomarkery $x krev $x genetika $x moč $7 D014408
650    _2
$a karcinom z renálních buněk $x krev $x genetika $x moč $7 D002292
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x krev $x genetika $x moč $7 D007680
650    _2
$a lidé středního věku $7 D008875
650    _2
$a malá interferující RNA $x krev $x metabolismus $x moč $7 D034741
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fedorko, Michal $u Department of Urology, University Hospital Brno, Masaryk University, Brno, Czech Republic on.slaby@gmail.com fedorko.michal@fnbrno.cz.
700    1_
$a Machackova, Tana $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Mlcochova, Hana $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Svoboda, Marek $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Pacik, Dalibor $u Department of Urology, University Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Dolezel, Jan $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Stanik, Michal $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic on.slaby@gmail.com fedorko.michal@fnbrno.cz. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 36, č. 12 (2016), s. 6419-6423
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27919963 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20201116155028 $b ABA008
999    __
$a ok $b bmc $g 1199821 $s 974134
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 36 $c 12 $d 6419-6423 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
GRA    __
$a NV15-31071A $p MZ0
GRA    __
$a NV15-34678A $p MZ0
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...